Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

This analysis was conducted to inform dose selection of a combination of nivolumab plus ipilimumab for the treatment of sorafenib‐experienced patients with hepatocellular carcinoma (HCC). CheckMate 040 is an open‐label, multicohort, phase I/II trial in adults with advanced HCC that evaluated nivolum...

Descripción completa

Detalles Bibliográficos
Autores principales: Sangro, Bruno, Yau, Thomas, El‐Khoueiry, Anthony B., Kudo, Masatoshi, Shen, Yun, Tschaika, Marina, Roy, Amit, Feng, Yan, Gao, Ling, Aras, Urvi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432868/
https://www.ncbi.nlm.nih.gov/pubmed/37165980
http://dx.doi.org/10.1111/cts.13544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432868/
https://www.ncbi.nlm.nih.gov/pubmed/37165980
http://dx.doi.org/10.1111/cts.13544

Ejemplares similares